Up tókànItọsọna atẹle
AI ni Robotics Warehouse
Awọn ile-iṣẹ
Awọn ile-iṣẹ Itọsọna
AI ni Iṣẹ abẹ ati Robotics abẹ
Surgical robotics includes surgeon-controlled robotic-assisted systems and research on more autonomous tasks.
Gbọ si itọsọna yiiAI-ṣe afihan · ~2 min
Lori iwe yi2 min ka
Akopọ
AI methods may process images or assist planning, but clinical capability depends on the specific device and study.
Jin Dive
The da Vinci system is described by its manufacturer as surgeon-controlled robotic assistance. The STAR paper demonstrated supervised autonomous suturing of soft bowel tissue in animal models and describes stereo imaging, tissue-landmark detection and suture planning. The AVOID randomized phase 3 trial used ICG near-infrared fluorescence to assess bowel perfusion and adjust transection lines; its overall 90-day leakage rate was not significantly lower than conventional assessment. These examples do not establish universal autonomy or clinical benefit. In deformable-tissue surgery, tissue movement and visual constraints such as occlusion challenge image-based planning. The AVOID trial’s primary endpoint was clinically relevant anastomotic leakage within 90 days and showed no significant overall reduction with ICG fluorescence. The STAR animal study reports comparative consistency on specific measures including suture spacing and bite depth; it does not establish universal clinical superiority.
Real-World imuse
Intuitive describes da Vinci as a surgeon-controlled robotic-assisted system operated from a console.
The STAR research robot demonstrated supervised suturing of soft bowel tissue in animal models.
The STAR paper describes stereo imaging and tissue-landmark detection in its planning pipeline.
A randomized AVOID trial studied ICG near-infrared fluorescence for assessing bowel perfusion during colorectal surgery.
Ọjọ iwaju ti AI ni Iṣẹ abẹ ati Awọn Robotics abẹ
Research may test additional sensing and planning methods, but claims about clinical benefit, autonomy or regulatory expectations need evidence from a named device, study and jurisdiction. Preserving clinician oversight is presented here as a design recommendation.
Fifi o sinu iwa
Kini idi ti o ṣe pataki
- Ipo ati awọn ofin. Iyika ile-iṣẹ pinnu boya awọn imọran AI ye lọwọ olubasọrọ pẹlu otitọ.
- Iṣakoso didara. Awọn ihamọ agbegbe ni ipa awọn oṣuwọn aṣiṣe itẹwọgba ati awọn awoṣe abojuto.
- Kọ awọn yiyan. Awọn imuṣiṣẹ ti aṣeyọri ṣe deede agbara imọ-ẹrọ pẹlu ṣiṣan iṣẹ iwaju.
Ṣọra fun
- Awọn ibeere ilana le jẹ alaiṣe bibẹẹkọ awọn apẹẹrẹ ti o lagbara.
- Awọn data itan le ṣe koodu irẹjẹ ti o ṣe ipalara awọn agbegbe kan pato.
- Awọn eto Legacy le ṣẹda awọn igo iṣọpọ ati awọn idiyele ti o farapamọ.
Next awọn igbesẹ
- Fi awọn amoye agbegbe wọle lati idasile iṣoro si igbelewọn.
- Awọn itọpa iṣayẹwo apẹrẹ ati awọn iwe aṣẹ ṣaaju ifilọlẹ.
- Ṣe ifọwọsi ibamu ati awọn adehun ailewu ni kutukutu.
- Yi lọ jade ni awọn ipele pẹlu ko o Duro ati rollback àwárí mu.
Tesiwaju Ṣiṣawari
Ìwé ìròyìn ọfẹ
Gba ìkànìyàn AI ojoojúmọ́
Ìtàn AI mẹta tó jẹ́rìí ní gbogbo owurọ́ ọjọ́ iṣẹ́, kọ́wé ní Gẹ̀ẹ́sì tó rọrùn. Ọfẹ́ fún gbogbo àkókò, kò sí ìpolówó.
Ìmeèlì kan ní gbogbo ọjọ́ iṣẹ́. Yọkúrò ní ìkànìyàn ní ìkànìyàn kan. A kò ta tàbí pín àdírẹ́sì rẹ.
Ṣe idanwo fun ara rẹ
Take the AI in Surgery and Surgical Robotics quiz
Ìdáhùn lẹ́sẹ̀kẹsẹ̀ lórí gbogbo ìdáhùn, àti iwe-ẹ̀rí tó lè pin pẹ̀lú ID tó lè jẹ́rìí lẹ́yìn tí o bá kọ́ ẹ̀kọ́.
Ṣe àtìlẹ́yìn ẹ̀kọ́ AI ọfẹ́. AI Understanding jẹ́ àjọ àìní èrè 501(c)(3) — kò sí ìpolówó, kò sí àkúnya owó, ní gbogbo àkókò. Ṣe ẹbun kan
Awọn ibeere ti a beere nigbagbogbo
Kini AI ni Iṣẹ abẹ ati Roboti Iṣẹ-abẹ?
Surgical robotics includes surgeon-controlled robotic-assisted systems and research on more autonomous tasks. AI methods may process images or assist planning, but clinical capability depends on the specific device and study.
How does the manufacturer describe a da Vinci surgical system?
Intuitive describes da Vinci as a surgeon-controlled robotic-assisted system. This is a manufacturer-described capability, not a prevalence claim.
Kini robot STAR ṣe afihan ni awọn ikẹkọ ẹranko?
Robot Adase Tissue Smart Tissue (STAR) ni adase aran ara ailabawọn ifun inu elede, ti n ṣe agbejade awọn aṣọ aṣọ aṣọ diẹ sii ju awọn oniṣẹ abẹ eniyan ti o jẹ alamọja ni ifihan ala-ilẹ ti ominira abojuto.
Kini idi ti agbegbe iṣẹ abẹ paapaa nija fun iran kọnputa?
Ko dabi awọn ẹya ile-iṣẹ ti o ni lile, iṣan abẹ nigbagbogbo n yipada apẹrẹ ati pe o jẹ tutu, afihan, ati nigbagbogbo pamọ nipasẹ ẹjẹ, ẹfin cautery, ati awọn ohun elo, ti o jẹ ki ipin ti o gbẹkẹle ati titọpa nira.
What did the AVOID randomized trial find about ICG fluorescence and the overall 90-day colorectal anastomotic-leak rate?
The AVOID phase 3 trial reported no significant difference in overall 90-day clinically relevant leakage between fluorescence-guided and conventional groups. This is a study result, not a conclusion about every procedure or subgroup.
In the AVOID trial, what did ICG near-infrared fluorescence help surgeons assess?
The randomized AVOID trial used ICG fluorescence to assess bowel perfusion and adjust or keep transection lines. It did not significantly reduce the overall 90-day leak rate in the studied population.
Tesiwaju kikọ
Jẹmọ awọn itọsọna
Awọn itọsọna diẹ sii ti a yan fun koko yii